TY - JOUR
T1 - Ectopic Expression of PCSK9 by Smooth Muscle Cells Contributes to Aortic Dissection
AU - Iida, Yasunori
AU - Tanaka, Hiroki
AU - Sano, Hideto
AU - Suzuki, Yuko
AU - Shimizu, Hideyuki
AU - Urano, Tetsumei
N1 - Funding Information:
The authors are grateful to Y. Sano and T. Suzuki for the technical assistance. This work was supported by Grants-in-Aid for Scientific Research (C) (17K10765) to Y.I.; (C) (17K10751) to H.T., and Japan Heart Foundation Dr. Hiroshi Irisawa & Dr. Aya Memorial Research Grant to H.T.
Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2018/4
Y1 - 2018/4
N2 - Background: Acute aortic dissection (AAD) is a common disease among the elderly. Although several risk factors of AAD have been reported, the molecular mechanism underlying AAD development remains to be elucidated. Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases low-density lipoprotein cholesterol levels in blood by preventing its clearance. Therefore, PCSK9 inhibition is a promising therapeutic approach to treat cardiovascular diseases (CVDs). The objective of this study was to elucidate the role of PCSK9 in the pathogenesis of AAD. Methods: We used fluorescence immunohistochemistry to assess PCSK9 expression in aortic tissues resected from 10 AAD patients and in the normal aorta from 5 autopsy samples as well as in spontaneously hyperlipidemic apolipoprotein E-deficient mice used as an experimental AD model. Results: We revealed a characteristic distribution pattern of PCSK9 in atherosclerotic plaques and the degenerated tunica media in AAD tissues, which was rarely observed in normal aortic tissues. Furthermore, PCSK9 was notably expressed around calcification areas formed by vascular smooth muscle cells, especially those of the synthetic phenotype. The results obtained in the animal model were consistent with PCSK9 expression in AAD tissues. Conclusions: Our findings suggest that PCSK9 overexpression in the aorta may promote AAD. This study adds to the growing body of evidence supporting the use of PCSK9 inhibitors for the management of CVDs.
AB - Background: Acute aortic dissection (AAD) is a common disease among the elderly. Although several risk factors of AAD have been reported, the molecular mechanism underlying AAD development remains to be elucidated. Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases low-density lipoprotein cholesterol levels in blood by preventing its clearance. Therefore, PCSK9 inhibition is a promising therapeutic approach to treat cardiovascular diseases (CVDs). The objective of this study was to elucidate the role of PCSK9 in the pathogenesis of AAD. Methods: We used fluorescence immunohistochemistry to assess PCSK9 expression in aortic tissues resected from 10 AAD patients and in the normal aorta from 5 autopsy samples as well as in spontaneously hyperlipidemic apolipoprotein E-deficient mice used as an experimental AD model. Results: We revealed a characteristic distribution pattern of PCSK9 in atherosclerotic plaques and the degenerated tunica media in AAD tissues, which was rarely observed in normal aortic tissues. Furthermore, PCSK9 was notably expressed around calcification areas formed by vascular smooth muscle cells, especially those of the synthetic phenotype. The results obtained in the animal model were consistent with PCSK9 expression in AAD tissues. Conclusions: Our findings suggest that PCSK9 overexpression in the aorta may promote AAD. This study adds to the growing body of evidence supporting the use of PCSK9 inhibitors for the management of CVDs.
UR - http://www.scopus.com/inward/record.url?scp=85038969956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038969956&partnerID=8YFLogxK
U2 - 10.1016/j.avsg.2017.10.005
DO - 10.1016/j.avsg.2017.10.005
M3 - Article
C2 - 29197601
AN - SCOPUS:85038969956
SN - 0890-5096
VL - 48
SP - 195
EP - 203
JO - Annals of Vascular Surgery
JF - Annals of Vascular Surgery
ER -
